Tradestie Institutional Equity Comparison Engine
MEDI vs DNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MEDI Overall Edge
MEDI Captures Institutional Edge (2โ1 Pillars ยท 2โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harbor Health Care ETF (MEDI) driven by superior Momentum & Technical, Options & Structure while DNA counters with relative strength in Growth & Margin. Fundamentally, MEDI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, MEDI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MEDI N/M vs DNA N/M Fwd P/E
Growth & Margin Winner
DNA
Op Margin N/A vs -202.5% ยท YoY N/A vs -5.7%
Momentum & Technical Winner
MEDI
1Y +14.7% vs +6.2% ยท 52W Pos 90% vs 24%
Options & Structure Winner
MEDI
UNCLASSIFIED (N/A IV) vs BREAKDOWN (34th %ile IV)
MEDI
NYSE Arca
Harbor Health Care ETF
Institutional Equity
$35.59
-2.05% 1D
Market Cap
N/A
1M Return
+9.92%
1Y Return
+14.68%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 25.0
Fund 39.0
Flow 50.0
Mom 22.2
DNA
NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap
$623.0M
1M Return
-17.23%
1Y Return
+6.25%
Forward P/E
N/M
Unified AI Score
57.4 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MEDI +14.68%
DNA +6.25%
Spread: +8.43 pp (MEDI Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MEDI TTM Op. Margin: N/A
DNA TTM Op. Margin: -202.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MEDI vs DNA. Trailing 12-month operating profitability (MEDI N/A vs DNA -202.5%) and valuation multiples (MEDI N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MEDI | DNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $623.0M | Larger Scale | DNA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | -5.7% | Higher Growth | DNA |
| Operating Margin (TTM) Profitability | N/A | -202.5% | Higher Margin | DNA |
| Net Profit Margin Profitability | N/A | -192.0% | Higher Margin | DNA |
| Return on Equity (ROE) Capital Efficiency | N/A | -58.2% | Higher ROE | DNA |
| 52-Week Range Position Momentum | 90% ($28โ$37) | 24% ($5โ$18) | Stronger Trend | MEDI |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 22% Vol | 3.14ฮฒ ยท 152% Vol | Lower Realized Risk | MEDI |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 57.4 / 100 (HOLD) | Higher Composite | DNA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MEDI vs DNA Buy Guide
MEDI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
DNA
BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
34th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MEDI nor DNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.